NEW
Fasenra

Fasenra

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Benralizumab
Indications/Uses
Add-on maintenance treatment in adults from 18 yr w/ severe eosinophilic asthma who have at least 2 exacerbation in the past 12 mth on current standard therapy (high-dose inhaled corticosteroids + long-acting bronchodilators) &/or need for systemic corticosteroid treatment, or eosinophil blood count ≥300 cells/microliter.
Dosage/Direction for Use
30 mg SC inj every 4 wk for 1st 3 doses, then every 8 wk thereafter.
Contraindications
Special Precautions
Discontinue use if hypersensitivity reactions occur. Not to be administered in tender, bruised, erythematous or hardened skin. Not to be used for acute asthma exacerbations. Parasitic (helminth) infection. Avoid abrupt discontinuation of corticosteroids. Avoid use during pregnancy. Lactation. Childn 6-18 yr.
Adverse Reactions
Headache; pharyngitis; pyrexia, inj site reactions; hypersensitivity reactions.
ATC Classification
R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Fasenra soln for inj 30 mg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in